Biomarkers in heart failure
Wei-Chung Chen, Kimberly D Tran and Alan S Maisel

Heart 2010 96: 314-320
doi: 10.1136/hrt.2008.151639

Updated information and services can be found at:
http://heart.bmj.com/content/96/4/314.full.html

These include:

References
This article cites 23 articles, 14 of which can be accessed free at:
http://heart.bmj.com/content/96/4/314.full.html#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic collections
Articles on similar topics can be found in the following collections
- Heart failure (6 articles)
- Drugs: cardiovascular system (22857 articles)
- Heart failure (1147 articles)
- Hypertension (11933 articles)
- Epidemiology (4882 articles)

Notes

To order reprints of this article go to:
http://heart.bmj.com/cgi/reprintform

To subscribe to Heart go to:
http://heart.bmj.com/subscriptions
HEART FAILURE

Biomarkers in heart failure
Wei-Chung Chen, Kimberly D Tran, Alan S Maisel

Cardiovascular disease has emerged as one of the most prominent causes of morbidity and mortality among adult populations. As medical advances have enabled more patients to survive post-myocardial insult, the prevalence of congestive heart failure (CHF) has exploded. It is now estimated that 5 million people in the USA live with CHF, and that approximately 550,000 new cases are diagnosed each year. Hospitals for heart failure have increased dramatically from 402,000 in 1979 to 1,101,000 in 2004 (National Hospital Discharge Survey), and the cost of CHF is now estimated at US$56 billion a year, 70% of which is due to hospitalisation. Among a variety of proposed heart failure treatment modalities, cardiac biomarkers have emerged as powerful adjuncts to standardised clinical care in the diagnosis, prognosis, and treatment of acute heart failure (AHF).

Basics regarding natriuretic peptides (NPs)

B-type natriuretic peptide (BNP) is first synthesised in the myocytes as a 132 amino acid intracellular precursor known as preproBNP. During decompensation, volume overload and high pulmonary capillary wedge pressure cause the ventricle walls to stretch, triggering the cleavage and release of preproBNP as the biologically active 32 amino acid hormone BNP and its inactive N-terminal fragment (NT-proBNP). Once released, BNP has pronounced natriuretic, diuretic, and vasodilating properties, working to dramatically reduce volume overload and hypertension in patients. BNP is then believed to be removed quickly from circulation (half-life of 22 min) by both NP receptor endocytosis and endopeptidase enzymatic degradation. In contrast, NT-proBNP is suspected to be cleared from the plasma largely by renal excretion, and thus has slower fluctuations in circulating concentrations as well as a notably longer half-life of 60–120 min. In general, BNP and NT-proBNP values are reasonably correlated, and either can be used in patient care settings as long as their respective absolute values and cut points are not used interchangeably.

Diagnostic utility of NPs

In the Breathing Not Properly Multinational Study, BNP values from 1,586 patients presenting with dyspnoea to the emergency department (ED) were found to be more accurate in diagnosing heart failure than clinical examination alone (area under the curve (AUC) 0.91) (figure 1). A BNP cut point of 100 pg/ml was 90% sensitive and 76% specific for diagnosing heart failure. The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study, a randomised 599 dyspnoeic ED patients to NT-proBNP measurements to examine the marker’s clinical diagnostic utility in the setting of heart failure. Based on their results, the study investigators proposed an age independent NT-proBNP cut point of 300 pg/ml to ‘rule out’ AHF, introducing a measure in which patients might be screened before further costly examinations. However, since concentrations of NPs are known to increase with age, the investigators determined that a single NT-proBNP cut point would be inappropriate for the diagnosis of AHF in differing age groups, and thus proposed two different reference ranges for patients <50 years or ≥50 years of age (cut points 450 pg/ml and 900 pg/ml, respectively). These NT-proBNP cut points, when used alongside clinical assessment, were diagnostically superior to clinical judgement or NT-proBNP alone (AUC 0.94 vs 0.90, respectively).

These studies typify the success of incorporating NP measurements into the standard armamentarium of diagnosing heart failure in patients presenting with dyspnoea.

Prognostic utility of NPs

The prognostic potential of BNP was examined in the multicentre Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) study, and showed that BNP values were very strong predictors of 90 day outcomes. Among the 464 patients enrolled, the patients admitted with BNP concentrations >200 pg/ml had a much higher event rate of 29% when compared to that of patients admitted with BNP concentrations ≤200 pg/ml (9%) (table 1). Investigators observed a pronounced disparity between the ED physicians’ perception of CHF severity and the severity determined by BNP concentrations, and thus concluded that regular BNP assessment should be incorporated into standard clinical care to aid physicians in deciding who to admit from the ED.

In the International Collaborative of NT-proBNP (ICON) Study, 1,256 subjects recruited from multiple medical centres worldwide were examined for the prognostic potential of NT-proBNP in the setting of AHF. Heart failure patients with pronounced elevations in NT-proBNP concentrations had a more than fivefold increase mortality risk by 76 days, leading investigators to propose the NT-proBNP cut point of 5,180 pg/ml for predicting 76 day mortality in patients with AHF.

Biomarkers in heart failure

Wei-Chung Chen, Kimberly D Tran, Alan S Maisel

Cardiovascular disease has emerged as one of the most prominent causes of morbidity and mortality among adult populations. As medical advances have enabled more patients to survive post-myocardial insult, the prevalence of congestive heart failure (CHF) has exploded. It is now estimated that 5 million people in the USA live with CHF, and that approximately 550,000 new cases are diagnosed each year. Hospitals for heart failure have increased dramatically from 402,000 in 1979 to 1,101,000 in 2004 (National Hospital Discharge Survey), and the cost of CHF is now estimated at US$56 billion a year, 70% of which is due to hospitalisation. Among a variety of proposed heart failure treatment modalities, cardiac biomarkers have emerged as powerful adjuncts to standardised clinical care in the diagnosis, prognosis, and treatment of acute heart failure (AHF).

Basics regarding natriuretic peptides (NPs)

B-type natriuretic peptide (BNP) is first synthesised in the myocytes as a 132 amino acid intracellular precursor known as preproBNP. During decompensation, volume overload and high pulmonary capillary wedge pressure cause the ventricle walls to stretch, triggering the cleavage and release of preproBNP as the biologically active 32 amino acid hormone BNP and its inactive N-terminal fragment (NT-proBNP). Once released, BNP has pronounced natriuretic, diuretic, and vasodilating properties, working to dramatically reduce volume overload and hypertension in patients. BNP is then believed to be removed quickly from circulation (half-life of 22 min) by both NP receptor endocytosis and endopeptidase enzymatic degradation. In contrast, NT-proBNP is suspected to be cleared from the plasma largely by renal excretion, and thus has slower fluctuations in circulating concentrations as well as a notably longer half-life of 60–120 min. In general, BNP and NT-proBNP values are reasonably correlated, and either can be used in patient care settings as long as their respective absolute values and cut points are not used interchangeably.

Diagnostic utility of NPs

In the Breathing Not Properly Multinational Study, BNP values from 1,586 patients presenting with dyspnoea to the emergency department (ED) were found to be more accurate in diagnosing heart failure than clinical examination alone (area under the curve (AUC) 0.91) (figure 1). A BNP cut point of 100 pg/ml was 90% sensitive and 76% specific for diagnosing heart failure. The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study, a randomised 599 dyspnoeic ED patients to NT-proBNP measurements to examine the marker’s clinical diagnostic utility in the setting of heart failure. Based on their results, the study investigators proposed an age independent NT-proBNP cut point of 300 pg/ml to ‘rule out’ AHF, introducing a measure in which patients might be screened before further costly examinations. However, since concentrations of NPs are known to increase with age, the investigators determined that a single NT-proBNP cut point would be inappropriate for the diagnosis of AHF in differing age groups, and thus proposed two different reference ranges for patients <50 years or ≥50 years of age (cut points 450 pg/ml and 900 pg/ml, respectively). These NT-proBNP cut points, when used alongside clinical assessment, were diagnostically superior to clinical judgement or NT-proBNP alone (AUC 0.94 vs 0.90, respectively).

These studies typify the success of incorporating NP measurements into the standard armamentarium of diagnosing heart failure in patients presenting with dyspnoea.

Prognostic utility of NPs

The prognostic potential of BNP was examined in the multicentre Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) study, and showed that BNP values were very strong predictors of 90 day outcomes. Among the 464 patients enrolled, the patients admitted with BNP concentrations >200 pg/ml had a much higher event rate of 29% when compared to that of patients admitted with BNP concentrations ≤200 pg/ml (9%) (table 1). Investigators observed a pronounced disparity between the ED physicians’ perception of CHF severity and the severity determined by BNP concentrations, and thus concluded that regular BNP assessment should be incorporated into standard clinical care to aid physicians in deciding who to admit from the ED.

In the International Collaborative of NT-proBNP (ICON) Study, 1,256 subjects recruited from multiple medical centres worldwide were examined for the prognostic potential of NT-proBNP in the setting of AHF. Heart failure patients with pronounced elevations in NT-proBNP concentrations had a more than fivefold increase mortality risk by 76 days, leading investigators to propose the NT-proBNP cut point of 5,180 pg/ml for predicting 76 day mortality in patients with AHF.
INPATIENT MANAGEMENT OF AHF

As the prevalence of heart failure continues to rise, clinicians have looked increasingly towards NP as an objective index of heart failure severity and treatment adequacy. There are several reasons for this. First, BNP and NT-proBNP circulating concentrations correlate strongly with left ventricular end-diastolic wall stress, thus providing a surrogate measurement of severity of a patient’s heart failure, irrespective of clinical symptoms. Secondly, baseline NP values offer significant prognostic information, with follow-up NP measurement offering perhaps even more significance, as patients with the greatest fall in plasma NP concentrations have been shown to have the most favourable outcomes. Third, validated automated and point-of-care assays are widely available, making NP measurement quick and convenient for both patient and physician. Fourth, NP assays cost an average of US$20 per test, and can be used to carefully screen and monitor patients, thereby substantially reducing the costs of heart failure related hospitalisations and procedures. Finally, NP values have been shown to fall across diuretic, angiotensin converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), β-blocker, spironolactone, and nesiritide induced cardiac improvements, suggesting that NP guidance may prove extremely effective in determining the method and adequacy of heart failure treatment.

In the same way that blood pressure is used to guide hypertension management and cholesterol values for hypercholesterolaemia, NP values, as surrogate for left ventricular function and pulmonary capillary wedge pressure, may be used to guide the complex pharmacotherapy of CHF. A patient’s circulating NP concentrations may be thought to consist of two components: a ‘dry’ baseline component, as well as a ‘wet’ component, in which NP concentrations are acutely raised during decompensation due to the increased mechanical pressure and stretching of the ventricles. While empirical targets have been suggested for both BNP and NT-proBNP to optimise diagnosis and prognosis, ‘dry’ NP concentrations are known to vary appreciably between individuals due to clinical confounders such as gender, age, body mass index (BMI), and renal function; thus, universal cut points may not always be appropriate. In practice, a patient’s ‘dry’ NP value and NP changes during decompensation, treatment, and post-treatment may provide the most useful information in making clinical decisions.

In support of these assertions, Bayés-Genís et al. showed that in 100 heart failure patients monitored with NT-proBNP over 7 days of hospitalisation, those with an NT-proBNP drop of ≥50% had the highest survival rates, while those with a ≤15% drop were most likely to have future complications. Notably, the NT-proBNP percentage change post-treatment was superior to initial NT-proBNP values in the prognostication of patients. Additionally, Bettencour et al. showed in 50 decompenated heart failure patients that an initial NT-proBNP concentration of >6779 ng/l was highly predictive of readmission and death; however, a post-treatment NT-proBNP >4157 ng/l was even more predictive of future cardiac events, with an 8% increase in odds ratio for every 1000 ng/l above the cut point (p<0.0001). When comparing patients with >30% or <30% decrease in NT-proBNP concentrations, those with the greatest decrease had superior outcomes. The investigators also showed that patients discharged with a BNP concentration <250 pg/ml had a very strong prognosis for event-free survival, while failure of BNP values to decline over hospitalisation was a very strong predictor of death and/or readmission.

These findings present important implications for the reduction of hospital stay duration, rates of readmission, and direct costs of heart failure events. The B-type natriuretic peptide for Acute Shortness of breath Evaluation (BASEL) study, randomised 425 patients to BNP guided treatment and found that the use of BNP values decreased both hospital admissions (75% vs 85%) and intensive care unit admissions (15% vs 24%). Patients also had a decreased time to discharge (8 days vs 11 days).

Figure 1 Receiver-operating-characteristic curve for various cutoff values of B-type natriuretic peptide (BNP) in differentiating between dyspnea due to congestive heart failure (CHF) and dyspnea due to other causes. Reprinted with permission from Maisel et al.

Table 1 Percentages of various outcomes for admitted patients divided into groups based on a BNP cut point of 200 pg/ml. Reprinted with permission from Maisel et al.

<table>
<thead>
<tr>
<th>Admitted patients</th>
<th>BNP &lt;200 pg/ml (n = 43)</th>
<th>BNP &gt;200 pg/ml (n = 364)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>NYHA functional class III and IV</td>
<td>66%</td>
<td>70%</td>
<td>0.598</td>
</tr>
<tr>
<td>Combined event rate</td>
<td>9%</td>
<td>28%</td>
<td>0.006</td>
</tr>
<tr>
<td>Mortality</td>
<td>2%</td>
<td>9%</td>
<td>0.142</td>
</tr>
</tbody>
</table>

Combination therapy includes cardiac related admissions or visits, or all cause mortality. BNP, B-type natriuretic peptide; NYHA, New York Heart Association.
without any increase in rehospitalisations. Perhaps most notably, BNP guided treatment led to a total cost reduction of 26%, which could represent hundreds of millions in savings if applied nationwide. Even this is an underestimation, as BNP values probably account for a number of corrected diagnoses. Another potential reduction of cost was noted in the REDHOT study\(^5\) in which 11% of the 464 patients enrolled were admitted with BNP values <200 pg/ml (clinical cut point associated with lower mortality). In 2001, there were 680 106 hospital admissions, with an average cost of $5414.68 per patient, meaning that if BNP values could have reduced admissions by that same 11%, an estimated $500 million in unnecessary healthcare costs could have been saved.

In light of these findings, Mohammed and colleagues\(^5\) have proposed an algorithm for BNP or NT-proBNP guided management of AHF patients: NP baseline values should be obtained upon presentation for patient diagnosis, triage, and in-hospital prognosis. The patient should be treated via proven therapeutic modalities, and after treatment a follow-up NP value should be obtained before patient discharge in order to determine adequacy of treatment and long term prognosis. For the best outcomes, the investigators proposed the empirical targets of a ≥50% decrease in NP concentrations over the duration of the hospitalisation, with a discharge BNP target of <550 ng/l and/or NT-proBNP target of <4000 ng/l.

**OUTPATIENT MANAGEMENT OF CHF**

As in hospitalised patients, NPs can be easily used in outpatient settings to monitor patients and dramatically reduce their risk of new cardiac events and death. In the STARS-BNP study (Systolic Heart Failure Treatment Supported by BNP),\(^6\) 220 heart failure patients (New York Heart Association (NYHA) functional class II–IV) were randomised to BNP guided treatment with a BNP target <100 ng/l. At 5 months, the BNP cohort was seen twice as often for scheduled follow-up with more changes to their heart failure medications (134 vs 66, \(p<0.05\)), and ended with higher achieved doses of ACE inhibitors and \(\beta\)-blockers. However, they were also found to be less likely to decompensate, and through the median 15 months of follow-up, patients in the BNP cohort had far fewer heart failure related readmissions and/or deaths (25% vs 52%, \(p<0.001\)). Troughton et al\(^14\) observed similar reductions in heart failure decompensations, hospitalisations, and mortality events (19 vs 54, \(p=0.02\)) when they randomised 69 heart failure patients to NT-proBNP guided treatment (target <1700 ng/l).

In the STARBRITe study (Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: Brain Natruretlic Peptide Versus the Clinical CongesTion ScorE),\(^15\) investigators assessed the value of individualised BNP targets during short term follow-up. The investigators found that while the number of days survived out of hospital did not change, ACE inhibitor and \(\beta\)-blocker use was optimised, while diuretics were less likely to be increased. These studies suggest that individualised NP targets may help optimise the use of proven therapeutic medications and may also decrease adverse events over time.

**CAVEATS: RENAL FUNCTION, BODY MASS INDEX, ‘GREY ZONE’ NP VALUES**

**Renal impairment**

Clinicians have often noted a high coincidence rate of CHF and chronic kidney disease (CKD), an observation that has become widely known as the ‘cardio-renal interaction’.\(^6\)\(^\text{16}\) Though the mechanisms and effects of such an interaction are not yet fully understood, notably higher NP concentrations have been reported in heart failure patients also suffering from CKD.\(^6\)\(^\text{16}\)\(^\text{17}\)

In a secondary analysis of the PRIDE study,\(^16\) previously discussed, the 599 dyspnoeic patients were also evaluated for interaction between NT-proBNP values and CKD. Renal insufficiency was closely related to risk factors for CHF, and those with CKD had a higher prevalence of CHF (all \(p<0.003\)). NT-proBNP values and glomerular filtration rate (GFR) were found to be inversely and independently related (\(p<0.001\)), and accordingly, worsening renal function was associated with cardiac abnormalities found on echocardiography. While NT-proBNP cut points of >450 pg/ml and >900 pg/ml produced a 85% sensitivity and 88% specificity for diagnosing acute CHF in age stratified patients with normal renal function (GFR ≥60 ml/min/1.73 m\(^2\)), in patients with impaired renal function (GFR <60 ml/min/1.73 m\(^2\)), a higher NT-proBNP cut point of 1200 pg/ml was still able to effectively maximise sensitivity and specificity of heart failure diagnosis at 89% and 72%, respectively. Therefore, these results suggest that in the case of CHF and CKD coincidence, classic NP guided algorithms may still be appropriate, though cut points need to be readjusted for renal function. In comparison to other clinical factors, NT-proBNP was found to be the strongest independent predictor of mortality (hazard ratio (HR) 1.57, \(p=0.0004\)), even in the presence of impaired renal function, leading investigators to confirm the auspicious role of NT-proBNP in heart failure prognosis, irrespective of renal function.

In an analysis from the Breathing Not Properly Multinational Study, McCullough et al\(^17\) reported a similar interaction between BNP and GFR. Investigators have proposed various explanations for the heightened NP values observed in patients with CKD. Some stipulate that the higher prevalence of concomitant cardiac abnormalities in CKD patients cause the ventricles to release more NPs into the bloodstream. Others argue that circulating NP concentrations are elevated due to the reduced clearance capacity of injured nephrons.\(^5\)

**Obesity**

Obesity is a known risk factor for cardiovascular disease. Though it is well established that NP values are notably lower in obese heart failure
patients than in non-obese patients, the implications of these lowered concentrations is not yet well understood. In a study to examine interaction between BNP values and obesity, Mehra et al divided 318 CHF patients into three BMI cohorts: lean, overweight, and obese (BMI <25 kg/m², 25–29 kg/m², and ≥30 kg/m², respectively). BNP values trended downwards across all three groups (p<0.01), and were significantly lower in obese patients versus non-obese patients (p=0.0007), though there was no significance found when comparing the lean and overweight cohorts. Interestingly, despite the distinct disparity in BNP values across BMI groups, the event rate among both obese (25%) and non-obese (29%) patients remained constant through 1 year. This finding has been supported in other studies, and has become widely recognised as ‘the obesity paradox’. From the data, it appears that obese heart failure patients, even with higher risks and prevalence for cardiovascular disease and heart failure, have equal and/or better survival rates than non-obese patients. The explanation for these improved outcomes is not yet clear; however, recent studies suggest that the suppression of NP response and the early manifestation of heart failure in obese patients may be accounted for, in part, by increased BNP clearance by natriuretic clearance receptors in adipose tissue, as well as a documented, intimate relationship between NPs and lipolysis.

One thousand three hundred and sixty-nine patients from the Breathing Not Properly Multinational Study were similarly evaluated for BNP and BMI interaction. BNP values were found to be suppressed in obese patients, with a mean BNP concentration of 516.7±505.9 pg/ml in patients with BMI <20 kg/m², and of 176.3±270.5 pg/ml in those with BMI ≥40 kg/m², representing an almost threefold difference across the two BMI extremes. A univariate correlation was found between BMI and log BNP; however, in multivariate analysis adjusted for sex, GFR, race, CHF severity, and abnormal S3 sounds, no independent correlation between BNP and BMI was found. Thus, the investigators concluded that much of the inverse relationship between BNP and BMI might, in fact, be due to these clinical confounders and not to any specific obesity–NP interaction.

Grey zone

In most dyspnoeic patient populations, investigators have not been able to identify a single cut point to empirically rule in or rule out every patient with heart failure. This observation is in keeping with clinically guided, often non-specific, algorithms in which binary ‘black or white’ diagnoses are customarily inappropriate. It appears, then, that two cut-off points are necessary to screen patients adequately and reduce costs: one to effectively rule out heart failure in mildly dyspnoeic patients and eliminate unneeded hospitalisations, and another to rule in diagnosis and trigger prompt, appropriate treatment. The problem arises, then, necessarily in the ‘grey zone’ between these two cut points in which NP concentrations cannot be utilised as summarily to guide management decisions.

Van Kimmenade et al studied 215 patients with intermediate NT-proBNP concentrations, approximately half of whom were diagnosed with heart failure. Irrespective of their final diagnosis, subjects with ‘grey zone’ NT-proBNP values were found to have intermediate mortality rates between the high mortality rates of patients with heart failure and diagnostically high NT-proBNP concentrations, and the low mortality rates of those without heart failure and NT-proBNP concentrations <500 ng/l. Additionally, investigators found that adding specific clinical information to intermediate NT-proBNP values increased diagnostic accuracy, suggesting that a grey zone NT-proBNP value is still useful, and should signal further clinical examination.

In the REDHOT study, investigators documented similar findings in the 155 patients presenting with BNP concentrations ranging from 100–500 pg/ml. While there was no difference in the perceived NYHA class (p=0.32) or admission rate (p=0.76) of these patients, they were found to have fewer events than their non-grey zone counterparts through 90 days (19.2% vs 32.9%, p=0.002). Investigators thus concluded that irrespective of their clinical symptoms, patients with grey zone BNP values have a better prognosis than those in the non-grey zone composite.

These two studies show that though a grey zone NP value is often not as revealing in heart failure diagnosis, it should not be considered entirely uninformative. Rather, an NP value that falls within an intermediate range should be a signal for further clinical examination, and may still aid in patient prognosis.

TROPONIN

The cardiac troponins, troponin I (cTnI) and troponin T (cTnT), are proteins located in the myocytes that are responsible for the regulation of cardiac muscle contraction. Often used interchangeably in a qualitative fashion (ie, ‘positive’ or ‘negative’), ‘positive’ troponin values have long been associated with myocardial necrosis, and have also been shown to be excellent diagnostic and prognostic biomarkers in acute coronary syndromes. However, to date, very few studies have addressed the role of troponins in patients with heart failure. In a watershed study conducted by Peacock et al, the investigators examined 67,924 acutely decompensated heart failure (ADHF) patients admitted with known troponin values to explore the relationship between elevated troponin concentrations and adverse events in patients hospitalised for ADHF. Patients who were positive for troponin (defined as cTnI≥1.0 μg/l or cTnT≥0.1 μg/l) had a higher rate of in-hospital mortality than troponin negative patients (8.0% vs 2.7%, p<0.001), independent of other predictive variables. Analysis in the study indicated that in-hospital mortality within 1 day after admission was higher for troponin-positive than for troponin-negative patients.
This disproportionately high mortality rate, along with the longer hospitalisations and increased cardiac procedures associated with the positive troponin cohort in this study, suggest that troponin measurement should play a vital role in the early risk assessment and triage of patients presenting to the ED with ADHF.

**ST2: NOVEL BIOMARKER FOR PATIENTS WITH HEART FAILURE**

Recent interest has arisen in the prognostic capability of the novel interleukin-1 receptor family member ST2 in patients suspected of having heart failure. In a state of acute myocardial stretch, the ST2 gene is notably upregulated, and elevated serum concentrations have been reported in patients with heart failure. Januzzi et al. measured ST2 concentrations in 593 dyspnoeic patients presenting to the ED and found that though NT-proBNP was superior to ST2 in diagnosing ADHF, there was a very strong relationship between ST2 concentrations and 1 year mortality (HR 5.6, \( p < 0.001 \)). The median concentrations of ST2 were significantly higher among heart failure patients than non-heart failure patients, and in those who died than in survivors (1.03 ng/ml vs 0.18 ng/ml; \( p < 0.001 \)) (figure 3). Elevation of the ST2 marker was associated with the highest rate of death in patients with ADHF, and investigators suggested that a multi-marker approach using both ST2 and NT-proBNP might be the most effective approach in determining prognosis of ADHF patients.

**MID-REGION BIOMARKERS**

As the limitations of BNP and NT-proBNP become more clear, investigators have begun to look at mid-region biomarkers as alternatives outside the classic BNP/NT-proBNP dominated paradigm. Mid-region A-type NP (MR-proANP) and mid-region adrenomedullin (MR-proADM) have generated the most attention as potential new markers for several reasons. Both MR-proANP and MR-proADM are derived from precursor active peptides (ANP and ADM) which are released into circulation in response to cardiovascular fluid imbalance, as seen in BNP and NT-proBNP. These mid-regional markers can be easily measured by standard sandwich immunoassay technology and are much more stable than their active peptide counterparts, thus rendering them incredibly well suited for clinical settings as surrogate markers for their respective mature hormones.

The Biomarkers in Assessment of Congestive Heart Failure (BACH) multinational study closely examined the diagnostic and prognostic capability of these two markers in comparison to BNP and NT-proBNP among 1636 presenting to the ED with shortness of breath.

When comparing a MR-proANP cut point of 120 pmol/l to a BNP cut point of 100 pg/ml in diagnosing heart failure, MR-proANP sensitivity, specificity, and accuracy all fell within the non-inferiority margin of 10% (\( p < 0.0001 \)), showing that MR-proANP was non-inferior to BNP as a diagnostic tool for heart failure (figure 3). Additionally, the study investigators concluded that MR-proANP added significantly to the diagnostic performance of BNP (especially in the presence of clinical confounders), and that using MR-proANP in conjunction with clinical assessment further reduced physician diagnosis indecision by 29%.

With prognosis, the BACH study found that MR-proADM was superior to both BNP and NT-proBNP in predicting 90 day mortality in dyspnoeic patients presenting to the ED and diagnosed with heart failure. MR-proADM added significantly to the prognostic utility of both BNP and NT-proBNP, and was particularly strong in predicting 30 day survival, as indicated by the area under the receiver operating curves (AUC) of MR-proADM (0.739), BNP (0.555), and NT-proBNP (0.641). These findings led the BACH investigators to conclude that...
MR-proADM values can add significantly to existing prognostic biomarkers and help identify patients who should receive higher priority in the ED.

NEW BIOMARKERS FOR HEART FAILURE

The biomarker horizon continues to expand as investigators tirelessly look to improve heart failure recognition and treatment. Of late, both galectin-3 and growth differentiation factor 15 have generated some interest, and have proven themselves worthy of further exploration. Galectin-3 is a protein produced by activated cardiac macrophages during an inflammatory response. As inflammatory mechanisms have been identified as potential facilitators of heart failure progression, galectin-3 has been described in the literature as a potential biomarker for patients with heart failure. In a multi-marker analysis of 599 dyspneic patients presenting to the ED, van Kimmernade et al 89 showed that serum galectin-3 concentrations were significantly elevated in patients with heart failure in comparison to those without, and that galectin-3 had a greater AUC of 0.74 (p=0.0001) than NT-proBNP in predicting 60 day mortality. Galectin-3 added significantly to NT-proBNP’s prognostic capability, and thus provides encouraging support for the future development of multi-marker heart failure algorithms.

Growth differentiation factor (GDF)-15 has also recently emerged as a potential new biomarker for heart failure. A member of the transforming growth factor-β cytokine superfamily, GDF-15 expression is upregulated in the cardiac myocytes in response to mechanical stretch, and promotes antiapoptotic, anti hypertrophic, and anti-remodelling effects on the injured heart. Kempf et al 24 recently analysed 455 CHF patients with known GDF-15 concentrations, and showed that increasing values of GDF-15 translated to higher mortality risk in patients with heart failure. According to the study, after adjustments for known clinical variables and established prognostic biomarkers, GDF-15 remained an independent predictor of mortality (HR 2.26, p=0.001) and added important prognostic information to various patient subgroups, including those defined by age, BMI, heart failure aetiology, NYHA functional class, and left ventricular ejection fraction. These results suggest that GDF-15 may add prognostic information beyond that of current methods, and thus merits further exploration.

You can get CPD/CME credits for Education in Heart

Education in Heart articles are accredited by both the UK Royal College of Physicians (London) and the European Board for Accreditation in Cardiology—you need to answer the accompanying multiple choice questions (MCQs). To access the questions, click on BMJ Learning: Take this module on BMJ Learning from the content box at the top right and bottom left of the online article. For more information please go to: http://heart.bmj.com/misc/education.dtl

RCP credits: Log your activity in your CPD diary online (http://www.rcplondon.ac.uk/members/CPDiary/index.asp)—pass mark is 80%.
EBAC credits: Print out and retain the BMJ Learning certificate once you have completed the MCQs—pass mark is 60%. EBAC/EACCME Credits can now be converted to AMA PRA Category 1 CME Credits and are recognised by all National Accreditation Authorities in Europe (http://www.ebac-cme.org/newsite/?hit=men02).

Please note: The MCQs are hosted on BMJ Learning—the best available learning website for medical professionals from the BMJ Group. If prompted, subscribers must sign into Heart with their journal’s username and password. All users must also complete a one-time registration on BMJ Learning and subsequently log in (with a BMJ Learning username and password) on every visit.

REFERENCES


First article that truly examined the diagnostic potential of B-type natriuretic peptide in patients with heart failure.


Key article demonstrating the importance of incorporating NT-proBNP values in the diagnosis of heart failure in dyspneic patients.


Valuable article that fully explores the prognostic potential of B-type natriuretic peptide.


Important article indicating the prognostic capabilities of NT-proBNP in the management of patients with heart failure.


Very clear and useful article to guide clinicians in the management of heart failure patients using natriuretic peptide values.


Maisel AS. Use of BNP levels in monitoring hospitalized heart failure patients with heart failure. Heart Fail Rev 2003; 8:339—44.


Key article showing that the measurement of troponin concentrations can add valuable information to the prognostic of patients with acute decompensated heart failure.


One of the few articles that provide evidence of the prognostic potential of galectin-3 for the evaluation of patients with acute heart failure.